{
    "clinical_study": {
        "@rank": "159910", 
        "acronym": "TAVAB", 
        "arm_group": {
            "arm_group_label": "Bortezomib (Velcade)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The aim of this pilot study is to investigate the application of proteasome inhibitor\n      Bortezomib (Velcade\u00ae, approved for therapy of multiple myeloma) in patients with\n      therapy-refractory antibody-mediated autoimmune diseases. The investigators  hypothesis is\n      that the proteasome inhibition will lead to reduced antibody titers and improved clinical\n      outcome."
        }, 
        "brief_title": "Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)", 
        "condition": [
            "Myasthenia Gravis", 
            "Systemic Lupus Erythematosus", 
            "Rheumatoid Arthritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid", 
                "Autoimmune Diseases", 
                "Lupus Erythematosus, Systemic", 
                "Myasthenia Gravis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "(main) Inclusion Criteria:\n\n          -  age 18 - 75 years at screening\n\n          -  ability to give written consent, informed written consent\n\n          -  negative pregnancy test at screening\n\n          -  therapy-refractory Myasthenia Gravis (generalized) or Systemic Lupus Erythematosus or\n             Rheumatoid Arthritis\n\n        (main) Exclusion Criteria:\n\n          -  Belimumab therapy within the last 6 months\n\n          -  B-cell-depletion therapy within the last 9 months\n\n          -  heart or kidney insufficiency\n\n          -  known intolerability to Bortezomib\n\n          -  participation in another interventional trial within the last 3 months\n\n          -  liver cirrhosis\n\n          -  preexistent sensory or motor polyneuropathy  \u2265 degree 2 (NCI CTC AE criteria), within\n             14 days before screening\n\n          -  hints on clinically apparent herpes zoster reactivation\n\n          -  active systemic infection, or viral infection (CMV, EBV) within last 6 month before\n             screening\n\n          -  serologically active hepatitis B and /or C, known HIV infection\n\n          -  tumor disease currently or within last 5 years\n\n          -  clinically relevant liver, kidney or bone marrow function disorder\n\n          -  pregnancy or lactation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02102594", 
            "org_study_id": "TAVAB", 
            "secondary_id": "2013-005362-19"
        }, 
        "intervention": {
            "arm_group_label": "Bortezomib (Velcade)", 
            "description": "Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.", 
            "intervention_name": "Bortezomib", 
            "intervention_type": "Drug", 
            "other_name": "Velcade"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Bortezomib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Myasthenia Gravis", 
            "Systemic Lupus Erythematosus", 
            "Rheumatoid Arthritis", 
            "proteasome inhibitor", 
            "Bortezomib", 
            "Velcade", 
            "antibody-mediated autoimmune disease"
        ], 
        "lastchanged_date": "April 2, 2014", 
        "location": [
            {
                "contact": {
                    "email": "siegfried.kohler@charite.de", 
                    "last_name": "Siegfried Kohler, Dr. med.", 
                    "phone": "0049-30-450-639723"
                }, 
                "contact_backup": {
                    "email": "andreas.meisel@charite.de", 
                    "last_name": "Andreas Meisel, Prof. Dr.", 
                    "phone": "0049-30-450-660026"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Charite - Universit\u00e4tsmedizin Berlin, NeuroCure Clinical Research Center"
                }, 
                "investigator": {
                    "last_name": "Siegfried Kohler, Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "falk.hiepe@charite.de", 
                    "last_name": "Falk Hiepe, Prof. Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Internal Medicine / Rheumathology"
                }, 
                "investigator": {
                    "last_name": "Falk Hiepe, Prof. Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)", 
        "overall_contact": {
            "email": "andreas.meisel@charite.de", 
            "last_name": "Andreas Meisel, Prof. Dr.", 
            "phone": "0049-30-450-660026"
        }, 
        "overall_contact_backup": {
            "email": "siegfried.kohler@charite.de", 
            "last_name": "Siegfried Kohler, Dr. med.", 
            "phone": "0049-30-450-639723"
        }, 
        "overall_official": [
            {
                "affiliation": "Charit\u00e9 - Universit\u00e4tsmedizin Berlin, NeuroCure Clinical Research Center", 
                "last_name": "Andreas Meisel, Prof. Dr.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Internal Medicine / Rheumatology", 
                "last_name": "Falk Hiepe, Prof. Dr.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in disease specific antibody titers (anti-ACh for myasthenia gravis, anti-dsDNA for systemic lupus erythematosus, anti-ACPA for rheumatoid arthritis) 6 months after end of Bortezomib therapy (duration 6 weeks) compared to baseline (before therapy).", 
            "measure": "change in disease specific antibody titers after application of Bortezomib", 
            "safety_issue": "No", 
            "time_frame": "6 months after end of therapy (6 weeks) compared to baseline (before therapy)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02102594"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Charite University, Berlin, Germany", 
            "investigator_full_name": "Andreas Meisel", 
            "investigator_title": "Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in disease specific antibody titer after Bortezomib application (except at time point 6 months after end of therapy = primary outcome measure)", 
                "measure": "Change in disease specific antibody titer after Bortezomib application", 
                "safety_issue": "No", 
                "time_frame": "at regular intervals up to 30 weeks compared to baseline"
            }, 
            {
                "measure": "Change in quality of life (Qol score)", 
                "safety_issue": "No", 
                "time_frame": "at regular intervals up to 30 weeks compared to baseline"
            }, 
            {
                "measure": "Change in Activities of Daily Living (Adl score)", 
                "safety_issue": "No", 
                "time_frame": "at regular intervals up to 30 weeks compared to baseline"
            }, 
            {
                "measure": "change in dose of immunosuppressive co-medication", 
                "safety_issue": "No", 
                "time_frame": "at regular intervals up to 30 weeks compared to baseline"
            }, 
            {
                "description": "Change in titers of protective antibodies against measles virus, rubella virus, varicella zoster virus, pneumococcus, cytomegalovirus", 
                "measure": "Change in titers of protective antibodies (e.g. measles)", 
                "safety_issue": "No", 
                "time_frame": "at regular intervals up to 30 weeks compared to baseline"
            }, 
            {
                "description": "Change in number of antibody producing plasmablasts/cells in peripheral blood", 
                "measure": "Change in number of antibody producing plasmablasts/cells", 
                "safety_issue": "No", 
                "time_frame": "at regular intervals up to 30 weeks compared to baseline"
            }, 
            {
                "description": "Change in concentration of soluble mediators (e.g. IL-6) in peripheral blood", 
                "measure": "Change in concentration of soluble mediators (e.g. IL-6)", 
                "safety_issue": "No", 
                "time_frame": "at regular intervals up to 30 weeks compared to baseline"
            }, 
            {
                "measure": "need for hospitalisation", 
                "safety_issue": "Yes", 
                "time_frame": "at regular intervals up to 30 weeks"
            }
        ], 
        "source": "Charite University, Berlin, Germany", 
        "sponsors": {
            "collaborator": {
                "agency": "Prof. Dr. med. Falk Hiepe (Charit\u00e9, Internal Medicine / Rheumathology)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Charite University, Berlin, Germany", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}